Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Corcept Therapeutics Inc shares valued at $703,656 were sold by Guyer William on Jan 06 ’26. At $35.18 per share, Guyer William sold 20,000 shares. The insider’s holdings dropped to 1,235 shares worth approximately $44842.850000000006 following the completion of this transaction.
Also, Guyer William purchased 20,000 shares, netting a total of over 699,000 in proceeds.
Before that, Guyer William had sold 20,000 shares from its account. In a trade valued at $1,601,526, the Chief Development Officer traded Corcept Therapeutics Inc shares for $80.08 each. Upon closing the transaction, the insider’s holdings decreased to 20,000 shares, worth approximately $44842.850000000006.
As published in a research note from Wolfe Research on December 31, 2025, Corcept Therapeutics Inc [CORT] has been rated down from a Peer perform to an Underperform and the price target has been revised to $30. Analysts at UBS started covering the stock with ‘”a Neutral”‘ outlook in a report released in mid December. As of November 18, 2025, Wolfe Research has initiated its “Peer perform” rating for CORT. Earlier on November 06, 2023, Truist upgraded its rating. Their new recommendation was “a Buy” for CORT stock which previously was a “a Hold”.
Analyzing CORT Stock Performance
On last trading session, Corcept Therapeutics Inc [NASDAQ: CORT] rose 2.89% to $36.31. The stock’s lowest price that day was $35.0, but it reached a high of $37.5 in the same session. During the last five days, there has been a drop of approximately -0.11%. Over the course of the year, Corcept Therapeutics Inc shares have dropped approximately -34.35%.
Is Corcept Therapeutics Inc subject to short interest?
Stocks of Corcept Therapeutics Inc saw a sharp steep in short interest on 2025-12-31 dropping by -1.19 million shares to 9.15 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 10.34 million shares. A decline of -13.05% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.62 of the overall float, the days-to-cover ratio (short ratio) decline to 4.62.
Which companies own the most shares of Corcept Therapeutics Inc (CORT)?
In terms of Corcept Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 90 in the next 12 months, up nearly 155.03% from the previous closing price of $35.29. Analysts anticipate Corcept Therapeutics Inc stock to reach 99 by 2026, with the lowest price target being 30. In spite of this, 4 analysts ranked Corcept Therapeutics Inc stock as Buy at the end of 2026. On April 11, 2023, SVB Securities assigned a price target of “a Market perform” to the stock and initiated coverage with a $25.
